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Diabetes
Anca Pantea-Stoian, Roxana Adriana Stoica 
and Simona Diana Stefan
Abstract
The prevalence of gestational diabetes risen in several populations during the 
past 20 years, and increased direct and indirect healthcare costs, including those 
for insulin treatment. Establishing the optimal treatment and initiation momentum 
are critical to achieve glycemic control and minimize the impact on fetal develop-
ment and perinatal complications. Insulin is the only therapy that does not cross the 
placenta, and some of its types were proved to be safe in pregnancy. Intrapartum 
management is based on intravenous insulin administration, and standard protocols 
should be implemented in every center. Postpartum management requires special 
attention, as insulin necessary has a fast decline exposing mothers to hypoglycemia.
Keywords: gestational diabetes, insulin therapy, macrosomia, neonatal hypoglycemia
1. Introduction
Gestational diabetes (GD) is one of the most common pathologies in pregnancy. 
Gestational diabetes has been defined as any degree of glucose intolerance with 
onset or first recognition during pregnancy [1]. In pregnancy, there are multiple 
hormonal changes, including hyperinsulinemia and an insulin-resistant state; thus 
the pancreatic beta cell function becomes insufficient to meet the body’s reasonable 
needs, and insulin must be injected.
There is also the possibility that hyperglycemia was present before the preg-
nancy; therefore International Association of Diabetes and Pregnancy Study 
Groups (IADPSG) defined the pregnancy hyperglycemia as either ‘overt diabetes’ or 
‘gestational diabetes mellitus’ (GDM) [2].
Considering the ascending trend of type 2 diabetes mellitus and obesity from 
the last decades, GD has intuitively the same tendency [3, 4]. The prevalence of GD 
is estimated at approximately 135,000 cases per year in the US [5], representing on 
average 3–8% of all pregnancies [6]. It is estimated that the prevalence of GD has 
increased by 10–100% in several racial groups during the past 20 years, increasing 
direct and indirect healthcare costs [5].
The goal of treatment for women with GD (recommended by both American 
Diabetes Association-ADA, and the American College of Obstetricians and 
Gynecologists-ACOG) is a fasting plasma glucose level <95 mg/dl, a 1-hour post-pran-
dial glucose level of less than 140 mg/dl and a 2-hour post-prandial glucose level of 
less than 120 mg/dl, whereas for the HbA1c the target is <6–6.5% (42–48 mmol/mol); 
lower HbA1c—6% (42 mmol/mol) is optimal if it can be achieved without significant 
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hypoglycemia; also, the target may be relaxed to 7% (53 mmol/mol) in order to prevent 
hypoglycemia [7, 8].
2. Lifestyle intervention
After diagnosis GD, to reach the goals for plasma glucose levels, the first step 
is the initiation of a lifestyle intervention program (including medical nutrition 
therapy—MNT and physical activity—PA).
MNT is the cornerstone of the GDM treatment. MNT alone can assure glycemic 
targets in 80–90% of GDM patients [9]. Maternal height and weight are key factors 
for the medical nutrition therapy, providing adequate calories and nutrients for 
both maternal and fetal nutrition, maintaining glycemic targets and the absence of 
ketones with appropriate weight gain [10–12]. For a GDM mother with a normal 
body mass index (BMI) of 18.5–24.9 kg/m2, the number of adequate calories is 
about 30 kcal/kg [9]. Nevertheless, since more than 60% of women diagnosed with 
GDM are overweight or obese, a caloric restriction is needed. The ADA states that 
no research identifies a specific optimal calorie intake for women with GDM and 
that the calorie needs are no different from those of pregnant women without GDM 
[7]. Therefore, ADA issued only general recommendations (following the dietary 
reference intakes) for 175 g of carbohydrate, 71 g of protein, 28 g of fiber, emphasiz-
ing the importance of the amount and type of carbohydrate with significant impact 
concerning the glucose levels, especially postprandial glucose peak [7]. ADA recom-
mends individualized nutrition plan developed by a registered dietitian familiar with 
the management of GDM [7]. The National Institute for Health and Care Excellence 
(NICE) guidelines recommend a healthy diet, emphasizing the importance of low 
glycemic index foods (that should replace those with a high glycemic index) for GDM 
women; also there is the recommendation for a dietitian when GDM is present [13].
The carbohydrate intake should be reduced to 33–45% of the total calories, and 
distributed over 3 meals, and 2–4 snacks/day, thus reducing postprandial glucose 
peak [8, 14], while as the rest of the calories should be divided between protein (20%) 
and lipids (40%) [15].
Excessive weight gain during pregnancy should be avoided for GDM women 
[16]. The weight gain during pregnancy depends on pre-pregnancy BMI:
• 12.5–18 kg of weight gain for underweight women (BMI <18.5 kg/m2);
• 11.5–16 kg for normal weight (BMI 18.5–24.9 kg/m2);
• 7–11.5 kg for overweight (BMI 25–29.9 kg/m2)
• 5–9 kg for obese (BMI ≥30.0 kg/m2) [17]
Physical activity improves glycemic control in GDM women. The generally accepted 
recommendation is daily moderate-intensity regular exercise (walking 30 minutes/day 
or more—if no medical contraindications) improves blood glucose control [13, 14].
3. Pharmacological treatment
Pharmacological treatment is recommended when lifestyle intervention does 
not reduce hyperglycemia to reach the glycemic target. There is no international 
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consensus on when to start pharmacological treatment of GDM [18]. The Canadian 
Diabetes Association (CDA) and NICE guidelines, both recommend beginning 
pharmacological treatment if glycemic control is not achieved after 1–2 weeks of 
lifestyle intervention [13, 19].
Oral antidiabetic medication has been described in a previous chapter. The 
authors want to resume the most important clinical implications and the compari-
sons with insulin treatment.
3.1 Metformin
The use of metformin in GDM after the glycemic target is not reached with 
lifestyle intervention is recommended by the NICE guidelines [13]. Metformin is 
classified as a category B drug, which implies that there is no evidence of animal, 
or fetal toxicity or teratogenicity. In general, metformin appears to be a safe alter-
native to insulin for the GDM treatment, but it crosses the placenta, and it may 
be present in a higher concentration in the fetal circulation than in the maternal 
circulation [19]. Studies were performed for the assessment of metformin expo-
sure in-utero. There is no evidence that the metformin is affecting the fetus with 
regards to an early motor, linguistic, social, [20], metabolic [20, 21], and neuro-
developmental [22, 23] outcomes, but long-term follow up studies are needed. 
The metformin was associated with a lower risk of neonatal hypoglycemia and 
less maternal weight gain than insulin in two systematic reviews [24, 25]. Almost 
half of the patients with GDM who were initially treated with metformin needed 
insulin to achieve acceptable glucose control [26]. Metformin remains an option as 
a second line treatment in GDM women who refuse insulin treatment or who are 
unable to administer insulin safely.
3.2 Glyburide
Glyburide (glibenclamide) was associated with increased birth weight, macro-
somia and neonatal hypoglycemia compared with insulin [20, 25], and similar to 
metformin, crosses the placenta [27]. Glyburide therapy during pregnancy is not 
recommended as first- or second-line treatment, but it may be used as third-line 
treatment if insulin is refused, and metformin is either refused or insufficient to 
reach targeted glycemic control [19].
There is no human data for the use of any other antihyperglycemic medication in 
the treatment of GDM (DPP-4 inhibitors, GLP-1 receptor agonists or SGLT2 inhibi-
tors) [19]. Patients treated with oral therapy should be informed that they cross the 
placenta. No adverse effects on the fetus have been demonstrated; long-term studies 
are lacking [7].
3.3 Insulin therapy
Insulin is the first-line antihyperglycemic medication recommended for treat-
ment of GDM [7, 19]. None of the currently available insulin preparations has 
been demonstrated to cross the placenta [7]. If glycemic control is not achieved 
after 1–2 weeks of lifestyle intervention, insulin treatment should be initiated 
[19]. Insulin remains the gold standard treatment for GDM women that do not 
reach glycemic targets with lifestyle intervention, as recommended by several 
guidelines (see Table 1 below). Insulin use reduces fetal and maternal morbidity 
[28, 29].
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3.3.1 Types of insulin
3.3.1.1 Human insulin
3.3.1.1.1 Regular insulin
Regular insulin (U-100, U-500) is identical to human insulin, and it is used as meal-
time insulin to cover postprandial hyperglycemia. Its time to onset is about 30 minutes 
(10–75 minutes), the peak effect is in 3 hours (2.5–5 hours), and the effect ends at 
about 8 hours (up to 24 hours for U500). The FDA pregnancy category is B [30].
3.3.1.1.2 Human insulin inhalation (nasal insulin)
Human insulin inhalation (nasal insulin) is equivalent unit-for-unit to insulin 
lispro. Its onset is 15 minutes, and its peak action time is ∼50 minutes. Duration of 
action is about 2 hours. Inhaled human insulin carries a boxed warning for broncho-
spasms in patients with chronic lung disease. It is a pregnancy category C drug [30].
3.3.1.2 Rapid-acting insulin analogs
Another analog of human insulin is insulin aspart produced from Saccharomyces 
cerevisiae, a type of yeast. Aspart should be taken 5–10 minutes before a meal. It 
can be used like for multiple subcutaneous injections or in insulin pumps. Its peak 
action time is 40–50 minutes, and its duration of action is 3–5 hours. Insulin aspart 
produce less hypoglycemia than the regular insulin [31]. The FDA pregnancy cat-
egory is B and can be used in pregnancy. Data from two clinical trials (349 exposed 
pregnancies) do not indicate any adverse effect on pregnancy or fetal/neonatal 
health compared with human insulin [30].
3.3.1.2.1 Insulin aspart
Insulin aspart was introduced on the market with nicotinamide and L-arginine 
hydrochloride as excipients to enhance its absorption. Although the active molecule 
is identical, there are no available data for its use in pregnancy and its excretion in 
human milk [30].
International Federation of Gynecology and 
Obstetrics (FIGO), 2015
 - Oral therapy failure or
 - One of the risk factors:
• Diagnosing diabetes before 20 weeks of gestation
• Oral therapy for more than 30 weeks
• Fasting plasma blood glucose above 110 mg/dl
• 1-hour postprandial glycemia above 140 mg/dl
• Weight gain over 12 kilograms during pregnancy
Canadian Diabetes Association (CDA), 2018 If glycemic control is not achieved in 2 weeks after the 
initiation of medical, nutritional intervention
American Diabetes Association (ADA), 2018 First line therapy if glycemic control is not achieved after 
diet intervention
American College of Obstetricians and 
Gynecologists (ACOG), 2018
First line therapy if glycemic control is not achieved after 
diet intervention
Table 1. 
Insulin initiation recommendations.
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3.3.1.2.2 Insulin lispro
Insulin lispro (U-100 and U-200) is an analog produced in Escherichia coli 
cultures. Its onset of action is 10–15 minutes. The peak is at 30–90 minutes, and its 
duration of action is 3–4 hours. Also, it can be used in insulin pumps or pens. The 
U-100 and U-200 formulations have the same bioequivalence and pharmacokinet-
ics. The FDA pregnancy category is B and can be used in pregnancy. The data from a 
large number of exposed pregnancies do not indicate any adverse effect on preg-
nancy or fetal/neonatal health [30].
3.3.1.2.3 Insulin glulisine
Insulin glulisine is a recombinant insulin. It is obtained using Escherichia coli. It 
works fast nearly in 10–15 minutes. Its peak installs in 55 minutes, and its full dura-
tion is 4–5 hours. Although it can be used in some insulin pumps, it is not approved 
for all pump brands. The FDA pregnancy category is C. In this case, the vigilance 
should be given when prescribing glulisine to pregnant women, and the drug 
should only be used if the potential benefit justifies the potential risk to the fetus. 
There are limited data (less than 300 pregnancy outcomes) from the use of insulin 
glulisine in pregnant women [30].
3.3.1.3 Intermediate insulin
3.3.1.3.1 Insulin isophane
Insulin isophane (NPH) is an intermediate-acting insulin. It is also produced in 
Escherichia coli. It is similar to human insulin and is presented in a liquid suspension. 
Its onset of action is maximum 2 hours, with an average peak of 4 hours. NPH full 
duration of action is 10–20 hours. No restrictions on use in gestational diabetes or 
pregnancy; do not cross the placental barrier. The FDA pregnancy category is B [30].
3.3.1.4 Basal analogs
3.3.1.4.1 Insulin detemir
Insulin detemir (U-100) is a long-acting analog produced in Saccharomyces 
cerevisiae. Detemir insulin lacks a defined peak and lasts for up to 24 hours, and 
time to onset of action can be 1–2 hours. The detemir insulin has less incidence of 
hypoglycemia compared to NPH regimen in pregnant women [32]. The FDA preg-
nancy category is B; considered during pregnancy. The potential benefit must be 
considered against the possible increased risk of adverse pregnancy outcomes. One 
clinical trial suggests a possible increased risk of serious adverse maternal outcomes 
compared with isophane insulin and data from an additional 250 outcomes from 
pregnant women exposed to insulin detemir suggest no maternal or fetal/neonatal 
toxicity [30].
3.3.1.4.2 Insulin glargine
Insulin glargine (U-100) is a long-acting analog produced in Escherichia coli. 
The acidic solution is neutralized in subcutaneous tissue, and micro precipitates are 
formed. These micro precipitates slowly release glargine over 24 hours. Its onset of 
action is 1–2 hours, its duration of action are 24 hours and has no peak. The FDA 
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pregnancy category was previously C, no human pregnancy data. May be consid-
ered during pregnancy, if necessary, but we do not have clinical data on exposed 
pregnancies from controlled clinical studies available. The data from pregnant 
women (between 300 and 1000 pregnancy outcomes) indicate no adverse effects 
on pregnancy, nor malformations or feto-neonatal toxicity [30].
3.3.1.4.3 Insulin glargine
Insulin glargine (U-300) is a long-acting insulin. It is not bioequivalent to 
glargine U-100, but it had the same structure and was approved in February 2015. 
Glargine U-300 is produced in Escherichia coli. Its peak action develops over 6 hours 
and continues for an entire 24 hours. The serum concentrations decline after 
16–36 hours. It is dosed once daily. There is no clinical experience until now with 
the use of insulin glargine (U-300) in pregnant women [30].
3.3.1.4.4 Insulin degludec
Insulin degludec U-100 and U-200 are considered bioequivalent. The insulin 
degludec’s mode of slow absorption and prolonged action is based on the forma-
tion of soluble multi-hexamers. Insulin degludec onset of action is nearly 1 hour 
and has no peak. It is dosed once daily. It can be dosed at any time of the day 
because of its long duration of action. There is no clinical experience in pregnant 
women [30].
3.3.2 Insulin regimens
There are many insulin regimens proposed for treating hyperglycemia, but 
the multiple daily injections (MDI) is by far the most efficient and the most 
flexible [33].
The insulin regimen should be chosen based on the blood glucose profile. 
Therefore, if fasting glycaemia is higher than 90–95 mg/dl, basal insulin 
should be initiated. It can be a long-acting insulin analog or neutral protamine 
Hagedorn. The basal insulin dose can be calculated according to the weight: 
0.2 units/kg/day.
If the hyperglycemia follows a meal, than rapid-acting insulin or regular insulin 
should be initiated before that m74eal (begin with 1 u of insulin for 10–15 g of 
carbohydrates).
Sometimes both fasting and postprandial glycaemia are elevated, thereby need-
ing MDI: 3 mealtime insulin and basal insulin. The total daily insulin requirement 
during the first trimester, is 0.7 units/kg/day, while in the second trimester it is 
0.8 units/kg/day, and in the third trimester, it is 0.9–1.0 units/kg/day. This does not 
necessarily fit all pregnancies. Usually, in pregestational diabetes, the total insulin 
dose is up to twice higher than in GDM.
In the case of morbid obesity, the initial doses of insulin can be increased to 
1.5–2.0 units/kg to overcome the combined IR of pregnancy and obesity [9].
Usually, the calculated total daily dose of insulin should be divided in two as 
for type 1 and type 2 diabetes: 50% as basal insulin at bedtime, and 50% divided 
between 3 meals and given as rapid-acting, or regular insulin before meals.
The doses of insulin have to be continuously optimized, so the self-monitoring 
blood glucose is essential.
Rapid-acting insulin analogs are preferred over regular insulin in pregnancy 
because there is a lower risk of hypoglycemia, and because they provide a better 
postprandial blood glucose control [29, 33].
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3.3.3 Insulin initiation
Insulin initiation is synthesized in Table 1.
3.4 Glycemic targets and control
Blood glucose control in important in gestational diabetes because it confers the 
future mother a sense of disease control and validation that diet and treatment are 
doing their effect as the glycemic control improves, the risk of maternal and fetal 
complications decreases, a principle that was demonstrated by HAPO study results 
[34]. The results of this landmark study and other seven randomized trials have been 
included in a Cochrane analysis that compared the treatment of gestational diabetes 
mellitus (GDM) with standard care. It demonstrated a lower risk of a composite 
endpoint (death, shoulder dystocia, humerus, clavicle fracture or nerve palsy), and 
also a lower risk of pre-eclampsia and macrosomia (birth weight over 4000 g or 90th 
percentile), with no differences between oral and injectable treatment [35].
Thereby, gestational auto monitoring and surveillance by an obstetrician in col-
laboration with the diabetologist, nutritionist and midwife is essential for achieving 
glycemic targets during pregnancy, labor and after birth. These targets are synthe-
sized in Tables 2 and 3.
3.5 Methods for glucose monitoring
3.5.1 Glycated hemoglobin (HbA1c)
Although glycated hemoglobin values must be interpreted with caution in 
patients with dilution anemia, iron deficiency anemia or other hematological 
5th International Workshop Conference Gestational 
Diabetes and International Association of Diabetes and 
Pregnancy Study Group, 2007
Capillary pre-prandial glucose <95 mg/dl 
(5.3 mmol/l)
Capillary 1 hour post-prandial glucose 
<140 mg/dl (7.8 mmol/l)
Capillary 2 hour post-prandial glucose 
<120 mg/dl (6.7 mmol/l)
FIGO, 2015 Capillary pre-prandial glucose <95 mg/dl 
(5.3 mmol/l)
Capillary 1 hour post-prandial glucose 
<140 mg/dl (7.8 mmol/l)
Capillary 2 hour post-prandial glucose 
<120 mg/dl (6.7 mmol/l)
CDA, 2018 Capillary pre-prandial glucose <95 mg/dl 
(5.3 mmol/l)
Capillary 1 hour post-prandial glucose 
<140 mg/dl (7.8 mmol/l)
Capillary 2 hour post-prandial glucose 
<120 mg/dl (6.7 mmol/l)
ADA, 2018 Capillary pre-prandial glucose <95 mg/dl 
(5.3 mmol/l)
Capillary 1 hour post-prandial glucose 
<140 mg/dl (7.8 mmol/l)
Capillary 2 hour post-prandial glucose 
<120 mg/dl (6.7 mmol/l)
Table 2. 
Glycemic targets during pregnancy.
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pathologies like minor thalassemia [36, 37], it proves to be useful in checking the 
self-reported date by the pregnant, especially if she is treated with insulin.
Other parameters that could be used for short-term (2–3 weeks) evaluation of 
blood glucose control is glycated albumin. It is not influenced by iron deficiency, but 
the values are low in nephrotic syndrome or thyroid disorders that sometimes are 
present in pregnancy. This marker was studied in GDM, but the cutoff limits are not 
precisely known with consideration of some population differences [38]. Molecules 
like fructosamine or 1,5-anhydroglucitol have not proven their utility [39–41].
3.5.2 Self-monitoring of capillary blood glucose (SMBG)
The efficiency of capillary blood testing (8 determinations per day) in pregnant 
diabetes patients has been demonstrated since the 1980s [42]. Current guidelines 
[7, 8, 12, 18] mention in general terms the frequency and optimal period (fasting, 
1 or 2 hours postprandial) when a test should be done without customizing for 
treatment, previous glycemic control.
In healthy adult pregnant women, 1-hour glycemia during a glucose challenge test 
was a better marker for insulin sensibility, being correlated with a fetal abdominal 
circumference in echography [43]. In Jovanovic and collab study [42], glycemia at 
1 hour after food intake in the third trimester was the best predictor for birth weight. 
Combs et al. used the same 1-hour glycemia to establish the best threshold (130 mg/dl) 
for which the risk for macrosomia and small for gestational age (SGA) is reduced [44]. 
Metzger was the one that proposed that 2-hours postprandial glycemia should be used 
in GDM with the limit of 120 mg/dl [34]. Two clinical studies compared the blood glu-
cose determination concluding that 1-hour glycemia is superior, but with two important 
biases—lack of randomization and low statistical power [45, 46].
A randomized clinical trial demonstrated that patients who adjusted insulin 
doses based on 1-hour postprandial glycemia had a lower risk of giving birth to a 
macrosomia, or to have a cesarean procedure; also, the risk for neonatal hypoglyce-
mia was smaller [47]. Not only the glycemic values per se is important, but also the 
pregnant women with GDM should be taught to estimate their carbohydrate intake 
and physical activity and adjust the insulin doses. Other factors that cannot be 
influenced are a hormonal secretion from the placenta, daily cortisol secretion vari-
ability that contributes to glucose excursions. Sivan et al. observed in their study a 
pattern in which 1-hour postprandial glycemia is abnormally raised in the morning, 
and 2 hours postprandial glycemia is abnormally raised in the evening [48].
The frequency of determination is as much as necessary. Based on a randomized 
control trial (RCT) the initial recommendation for SMBG is 4 tests per day, with the 
possibility to lessen the number of determinations according to if the patient has 
good control and the fetal morphology is normal [49]. In basal-bolus insulin-treated 
GDM 7 tests per day are recommended, but patient adherence is weak (a mean of 
4.2 in an observational study) [50].
The limit for SMBG consists in the accuracy bias: lowering hematocrit by 
dilution makes the capillary glucose to be overestimated. Some glucometers have 
included in their software functions to correct the hematocrit values, but the major-
ity uses colorimetric and amperometric methods that depend on it. Considering the 
tight glycemic control required during pregnancy and the fact that insulin doses are 
FIGO, 2015 Capillary glucose 72–126 mg/dl (4–7 mmol/l)
ACOG, 2018 Capillary glucose 70–110 mg/dl (3.9–3.1 mmol/l)
Table 3. 
Glycemic targets during labor.
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adjusted based on SMBG, some researchers recommend that the bias and impreci-
sion should be set at below 2% and the meters be verified according to international 
quality criteria [51].
3.5.3 Continuous interstitial glucose monitoring (glucose sensors, CGMS)
Systems for interstitial glucose monitoring have been used together with insulin 
pumps in type 1 diabetes pregnancies in RCTs and observational studies [52, 53]. In 
GDM pregnancies data come from small observational studies where they showed 
benefit for disclosing high and low glycemic excursions missed by SMBG [54].
Glycemic sensors can be used as a guide for therapy initiation, as demonstrated 
by Kestilä et al. [55]. The anti-diabetes medication was introduced in a higher 
proportion of GDM women with CGMS versus SMBG. Nevertheless, there were 
not any significant differences for the perinatal endpoints. The long-term impact 
of glycemic control during pregnancy is not known; therefore, the benefit of this 
intervention must be balanced with unnecessary treatment. The techniques for 
monitoring blood glucose are summarized in Table 4.
All these efforts in using the best method for monitoring insulin therapy 
in GDM are to maintain glycemic control for preventing fetal and maternal 
complications.
3.6 Fetal complications associated with insulin therapy
3.6.1 Neonatal hypoglycemia
Glucose is a nutrient that freely crosses the placenta from maternal to fetal 
circulation, to assure the energy required for growth. Immediately after birth, 
the glucose source disappears with a physiologic “hypoglycemia” in the blood of 
the newborn that triggers the secretion of counterregulatory hormones (glu-
cagon, steroids, catecholamines, growth hormone). In GDM pregnancies, the 
glycemia is continuously raised and determines a consecutive higher secretion 
of insulin that makes hypoglycemia more severe and prolonged than in normal 
newborns [56–59].
Regimen SBGM CGMS
GDM with diet or oral antidiabetics Fasting
1 hour postprandial
 - Fine-tune insulin dosing
 - Nocturnal hypoglycemia
 - Nocturnal hyperglycemia
 - Postprandial hyperglycemia
GDM with basal insulin Fasting
1 hour postprandial
Bedtime
GDM with premixed insulin Fasting
1 hour postprandial
Dinner preprandial
1 hour postprandial
GDM with basal bolus Fasting
Preprandial (lunch, dinner)
1 hour postprandial
Table 4. 
Insulin glucose monitoring techniques [adapted from American Association of Clinical Endocrinologist and 
American College of Endocrinology].
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Neonatal transient hypoglycemia could have implications in the neurocogni-
tive development as was shown by magnetic resonance imaging [60]. Also, it has 
psychological implications on the mother-child relationship because they are 
separated after birth for treatment. Hence, based on their study results, Voormolen 
et al. recommend screening all newborns from GDM women in the first 12 hours 
after birth because the majority of the events occur in this interval, with a higher 
incidence being in the insulin-treated group [58].
A series of studies demonstrated that newborns of GDM patients that were 
treated with metformin had fewer hypoglycemic events than those of women 
treated with insulin [21, 61]. Insulin analogs have a lower rise in postprandial glyce-
mic values without elevating hypoglycemic risk and should be preferred to human 
insulins [29, 33].
Regarding sulfonylureas, a meta-analysis demonstrated that glyburide treatment 
GDM had a higher risk of neonatal hypoglycemia and also macrosomia that the 
metformin-treated GDM [62].
3.6.2 Congenital anomalies
The relationship between insulin therapy and congenital anomalies was studied, 
especially in type 1 diabetes. The most important confounding factor is glycemic 
control. Although some case reports indicate an association between the use of 
insulin lispro and the risk of teratogenesis [63], another meta-analysis supports the 
fact that it is safe for use [64]. This risk could be explained by mitogenesis stimula-
tion by binding with a higher affinity for IGF-1 receptors. Lispro insulin has a 1.5 
and insulin glargine a 6.5 fold increase of receptor binding [65]. There are only 
retrospective studies that indicate glargine as safe insulin in pregnancy [66].
3.7 Birth complications associated with insulin therapy
3.7.1 Cesarean section (CS)
A Cochrane analysis of 1481 women with GDM showed that in the treatment 
group there was a higher number of induced labors versus the group with standard 
antenatal care, but with no difference regarding the number of births by CS [35]. 
Another meta-analysis did not demonstrate a correlation between the use of dif-
ferent types of insulin-like aspart, lispro and the birth by CS [67, 68]. Although the 
risk is not influenced by insulin treatment, it can be reduced by induction of labor 
(IOL) in 38th–39th week of gestation with better outcomes for the fetus [69].
3.7.2 Vacuum-assisted birth
Although pre-gestational diabetes raises the risk for vacuum assisted birth (shoul-
der dystocia, humerus, clavicle, skull fracture, Erb’s palsy, subarachnoidian or sub-
dural hemorrhages, asphyxia, convulsion), in GDM the risk was similar to that in the 
general population and could not be related to insulin therapy [68, 70]. A particular 
situation is with GDM that appeared in pregnancies obtained by assisted reproduc-
tive technology where the risk for perinatal and obstetrical complications is probably 
increased by the adverse effect of hyperglycemia, not by insulin treatment [71].
3.7.3 Fetal morbidity
Evidence that indicates a higher risk for fetal morbidity and mortality in GDM a 
scarce and less pronounced as in pre-gestational diabetes. Current decisions of IOL 
11
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as compared to expectant management should be individualized because the studies 
lack in this area. An RCT that showed that there is no difference between the two 
strategies regarding morbidity, but the IOL reduces the risk for shoulder dystocia in 
the macrosomic fetus [72]. The use of insulin analogs like detemir does not influ-
ence the morbidity [73].
3.8 Maternal complications associated with insulin therapy
3.8.1 Maternal hypoglycemia
Hypoglycemia threshold is specific for every individual. In pregnancy, there is 
a reduction of this threshold by 20% [74]. Patients with GDM that are treated with 
insulin must maintain a glycemia above 3.7 mmol/l (66 mg/dl) according to CDA, or 
above 3.9 mmol/l (70 mg/dl) according to ADA [7].
Insulin analogs are superior to human insulin because the hypoglycemic events 
are less frequent in type 1 diabetic pregnancies [75]. The use of multiple daily injec-
tions is as effective as continuous subcutaneous insulin infusion [76].
Maternal hypoglycemia affects the fetus just in severe cases when is associ-
ated with loss of consciousness or secondary to trauma. Also, it was observed that 
repeated episodes could lead to growth over the 90th percentile [77]. These episodes 
are more likely to be present in the first trimester in women who had pregestational 
diabetes than in GDM [74].
3.8.2 Hypertension
There is moderate quality evidence that indicates higher hypertension associ-
ated hypertension without giving details in insulin-treated GDM. This fact should 
be further researched because it is in contradiction with a non-modified risk for 
pre-eclampsia [68].
3.9 Intrapartum management
During the latent phase of labor hepatic gluconeogenesis is sufficient for provid-
ing the caloric requirements, but becomes exiguous during the active phase when 
intravenous glucose is perfused.
The study of Rosenberg and collab. demonstrated there is no significant dif-
ference in neonatal hypoglycemia, neonatal injury, Apgar score at 1–5 minutes in 
patients with insulin therapy that were managed with two approaches: dextrose 5% 
125 ml/h with a simultaneous insulin drip (adjustable rate 0.5–2.5 u/h) or dextrose 
5% alternating with ringer lactate (125 ml/h) and insulin introduction when the 
targets are exceeded [77]. Other researchers recommend dextrose 10% with an 
insulin drip [78].
Lowering maternal glycemia is necessary for preventing neonatal hypoglycemia, 
balancing this risk with that for ketosis. Capillary blood glucose should be tested 
every hour and urinary ketone bodies every time is possible [77]. ACOG agreed to 
the protocol proposed by Coustan [79] for maintaining a mean intrapartum glyce-
mic value of 100 mg/dl. For this, blood glucose should be tested every 2 hours with 
adjustments in insulin perfusion rates.
Women with GDM or type 2 diabetes, which were treated with oral therapy have a 
low insulin requirement and in most cases do not need treatment during labor. Thus, 
CDA recommends a “watchful waiting” and insulin initiation just in cases where 
glycemia is above 146 mg/dl (7.0 mmol/l) [19]. Ryan mentions the same principle in a 
review published before—if GDM pregnant had a necessary below 0.5 u/kg/day, they 
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could be initially monitored. Otherwise, patients with type 1 diabetes or type 2, GDM 
with a necessary above this limit will need insulin perfusions [78]. Insulin perfusion 
rates could be adjusted using sliding scales as proposed by Dude [80].
Although most of the studies use protocols for intravenous insulin administration, 
patients with insulin pumps can choose to keep their device during labor [81, 82]. This 
is recommended in centers with experience because during labor they can become 
unable to handle the pump given the pain, or some incidents like catheter avulsion 
could appear. In these cases, the patient is informed that a switch to an insulin drip is 
needed [19].
Another problem comes out when betamethasone is administered for premature 
birth. In patients with type 1 diabetes, an increase up to 40% of all doses during the 
next 5 days assures an adequate glycemic control [83]. A retrospective analysis of 
insulin drips in pregnant with GDM injected by a standard anticipatory protocol 
and with higher doses was associated with improving glycemic variability and 
decreasing by 25% the absolute risk for neonatal hypoglycemia [84].
3.10 Postpartum management
Insulin requirements drop quickly after giving birth and women are exposed 
to hypoglycemia. Patients with GDM usually do not need insulin, and women 
with type 1 and type 2 diabetes return to the previous regimen, but at doses that 
are at 60% of the antepartum necessary [85]. In the case where the doses are not 
remembered, half of the third-trimester dose could be injected. Another alterna-
tive is calculating dose per kilogram. With an insulin pump, the doctor will titrate 
downward the basal rate and boluses on a similar algorithm or adjust based on the 
information from glucose sensors for newer models.
Breastfeeding influences insulin sensibility: as the frequency of lactation 
increases, the HOMA and ISI (0, 120) have better values [86], so during breastfeed-
ing the insulin requirement falls by 10% [87].
3.11 Future research directions
There is a lot of missing evidence in optimal treatment for GDM. Insulin treat-
ment could be improved by developing automatic algorithms for calculating the 
appropriate doses like that proposed by Dinglas [88]. Moreover, fetal morbidity can 
be influenced by better monitoring like using glucose sensors that are more accurate 
in the hypoglycemic range [89–91].
Micro-RNAs are now extensively studied in different domains and might apply 
to diagnosing and selecting GDM patients that require insulin treatment [92].
Not eventually, the whole perspective of insulin therapy will change if the oral 
bioavailability of this peptide hormone will be enhanced. Polymeric nanocarriers 
and mucoadhesive discs were studied in diabetic rats and are the future expectation 
for mothers with diabetes [93].
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